Therapeutic Strategies Aimed at Improving Neuroplasticity in Alzheimer Disease

• Autores: Colavitta, María Florencia; Barrantes, Francisco José
• Año de publicación: 2023
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas
• Materia: ENFERMEDAD DE ALZHEIMER; COGNICION; NEUROPLASTICIDAD; NEUROTRANSMISORES; POTENCIADOR DE LARGO PLAZO; DETERIORO COGNITIVO; DEMENCIA; ENFERMEDADES NEURODEGENERATIVAS; NEUROINFLAMACION; TERAPIAS
• Institución: Pontificia Universidad Católica Argentina

Este artículo pertenece a un número especial llamado "New Discoveries in Drug Targets and Delivery for Alzheimer’s Disease", que se puede consultar desde el siguiente enlace: https://www.mdpi.com/journal/pharmaceutics/special_issues/30TR5812B9
Fil: Colavitta, María Florencia. Pontificia Universidad Católica Argentina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Colavitta, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: Colavitta, María Florencia. Pontificia Universidad Católica Argentina. Facultad de Psicología. Centro de Investigaciones en Psicología y Psicopedagogía; Argentina
Fil: Barrantes, Francisco José. Pontificia Universidad Católica Argentina. Instituto de Investigaciones Biomédicas; Argentina
Abstract: Alzheimer disease (AD) is the most prevalent form of dementia among elderly people. Owing to its varied and multicausal etiopathology, intervention strategies have been highly diverse. Despite ongoing advances in the field, efficient therapies to mitigate AD symptoms or delay their progression are still of limited scope. Neuroplasticity, in broad terms the ability of the brain to modify its structure in response to external stimulation or damage, has received growing attention as a possible therapeutic target, since the disruption of plastic mechanisms in the brain appear to correlate with various forms of cognitive impairment present in AD patients. Several pre-clinical and clinical studies have attempted to enhance neuroplasticity via different mechanisms, for example, regulating glucose or lipid metabolism, targeting the activity of neurotransmitter systems, or addressing neuroinflammation. In this review, we first describe several structural and functional aspects of neuroplasticity. We then focus on the current status of pharmacological approaches to AD stemming from clinical trials targeting neuroplastic mechanisms in AD patients. This is followed by an analysis of analogous pharmacological interventions in animal models, according to their mechanisms of action.